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Deleterious Germline BLM 
Mutations and the Risk for Early-
onset Colorectal Cancer
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Bloom syndrome is an autosomal recessive disorder characterized by chromosomal instability and 
increased cancer risk, caused by biallelic mutations in the RECQL-helicase gene BLM. Previous 
studies have led to conflicting conclusions as to whether carriers of heterozygous BLM mutations 
have an increased risk to develop colorectal cancer (CRC). We recently identified two carriers of a 
pathogenic BLM mutation in a cohort of 55 early-onset CRC patients (≤45 years of age), suggesting 
an overrepresentation compared to the normal population. Here, we performed targeted sequencing 
using molecular inversion probes to screen an additional cohort of 185 CRC patients (≤50 years of 
age) and 532 population-matched controls for deleterious BLM mutations. In total, we identified 
three additional CRC patients (1.6%) and one control individual (0.2%) that carried a known 
pathogenic BLM mutation, suggesting that these mutations are enriched in early-onset CRC patients 
(P = 0.05516). A comparison with local and publically available databases from individuals without 
suspicion for hereditary cancer confirmed this enrichment (P = 0.003534). Analysis of family members 
of the five BLM mutation carriers with CRC suggests an incomplete penetrance for CRC development. 
Therefore, these data indicate that carriers of deleterious BLM mutations are at increased risk to 
develop CRC, albeit with a moderate-to-low penetrance.
In autosomal recessive cancer predisposing syndromes such as Bloom syndrome (MIM2109000), 
Nijmegen breakage syndrome (MIM251260), and Fanconi anemia (MIM227650), the risk for cancer is 
age-dependent and varies between cancer types. Currently, evidence accumulates that also monoallelic 
mutations in the genes associated with these autosomal recessive syndromes, BLM, NBN and FANCC, 
respectively, may result in increased risks for cancer1–3. Heterozygous deleterious mutations in the DNA 
RECQL-helicase gene BLM have been associated with an increased risk for breast cancer3, but studies 
on the role of these mutations in susceptibility to CRC have been conflicting4–6. In Bloom syndrome 
patients, the lifetime risk for developing CRC is approximately 12%7. Previous research on heterozygous 
carriers of BLM mutations and CRC risk has mainly focused on the BLM founder mutation p.Y736 fs 
(BLMAsh) in the Ashkenazi Jewish population. Whereas Gruber et al. described that Ashkenazi Jews with 
CRC carry the BLMAsh allele more than twice as frequent as matched controls, Cleary et al.5 were unable 
to replicate these findings and Baris et al.6 did not find an increased risk for CRC in BLMAsh mutation 
carriers.
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Very recently, we performed whole-exome sequencing on a cohort of individuals diagnosed with 
CRC (n = 55) before the age of 45 years, and we identified two individuals with heterozygous BLM 
mutations that are known to play a role in Bloom syndrome (De Voer et al. unpublished data). To reveal 
whether these mutations contribute to the risk for CRC development, we have performed a case-control 
sequencing study using targeted enrichment by molecular inversion probe technology8 followed by Ion 
semiconductor sequencing to compare the prevalence of Bloom syndrome-causing mutations in patients 
with CRC and healthy controls.
Results
Frequency of BLM mutations in the general population. We previously identified deleteri-
ous BLM mutations, a splice site mutation (c.3558 + 1G > T) and a nonsense mutation (c.2695C > T; 
p.Arg899*), in two individuals that were diagnosed with colorectal cancer at the age of 29 and 37 years, 
respectively (Fig. 1a and Table 1; deVoer et al. unpublished data). Both mutations were reported in the 
Bloom’s syndrome registry, and are thus found in Bloom’s syndrome patients9. Since there are no precise 
numbers on the frequency of pathogenic BLM mutations in the general population, we queried the data 
browser from the Exome Aggregation Consortium (ExAC; n = 61,486)10, a publically available dataset 
containing exomes from individuals of European, African or Asian ancestry. We established an overall 
prevalence of known deleterious BLM mutations of approximately one in 900 individuals (0.11%), sug-
gesting that the prevalence of BLM mutations is enriched in our cohort of 55 early-onset CRC patients. 
To determine whether we could validate these findings, we managed to collect and analyse a cohort 
of 185 CRC patients diagnosed with CRC before the age of 50 years originating from the Netherlands 
Figure 1. Deleterious mutations in BLM in individuals with early-onset CRC. (a) Distribution of 
deleterious mutations identified in the CRC discovery cohort (red dots) and replication cohort (black 
dots) in BLM. Structural domains of the protein are indicated in colours. (b) Pedigrees of the individuals 
with deleterious BLM mutations. An arrow indicates the proband. Individuals with cancer and their age 
at diagnosis (if known) are marked as follows: breast cancer (B), bladder cancer (BC), brain tumour (BT), 
colon cancer (C), endometrial cancer (Ed), leukaemia (Leu), liver cancer (LC), pancreas cancer (Pa), 
melanoma (Me), prostate cancer (PC) and cancer of unknown origin (Ca).
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(n = 105) and Germany (n = 80), as well as a control cohort of 532 healthy individuals, for the presence 
of deleterious BLM mutations.
Targeted re-sequencing of BLM in cases and controls. For the targeted enrichment of the entire 
coding sequence of the BLM locus, we used molecular inversion probes (MIPs) technology, a recently 
developed method that facilitates high-throughput, multiplex sequence analyses, with high specificity for 
the target sequence8. The coding sequence of BLM, including the intron-exon boundaries, was targeted 
for 97.4% using 81 MIPs. The untargeted sequences involved two coding regions within exons 10 and 
13, which do not overlap with known pathogenic mutations (Supplementary Figure 1). Sequencing of 
the MIP amplified regions was performed using Ion Torrent PGM sequencing in eight different runs, 
containing between 89 and 138 barcoded samples per run. On average, 99.2% of the target sequence of 
the CRC cohort had a coverage of ≥ 10-fold (95.2% with ≥ 50-fold coverage), with a median coverage 
of 745-fold per probe (Supplementary Figure 2A). In the control cohort, on average, 98.7% of the tar-
get sequence was covered at least 10-fold (91.3% with ≥ 50-fold coverage), with a median coverage of 
320-fold per probe (Supplementary Figure 2B).
We identified heterozygous deleterious BLM mutations in three out of 185 CRC cases: one splice 
site mutation (c.98 + 1G > A) and two nonsense mutations (c.1642C > T; p.Gln548* and c.2695C > T; 
p.Arg899* mutation, 1.6%; Fig.  1a and Table  1), and in one out of 532 control samples (c.1642C > T; 
p.Gln548*, 0.2%), which points towards an enrichment in early-onset CRC cases compared to controls 
with borderline significance (OR = 8.67; 95% CI, 0.69–455.36; P = 0.05516). In addition, we analysed an 
in-house cohort of individuals without a suspicion for hereditary cancer for which high-quality exome 
sequencing data were available (n = 2,329; median exome coverage ≥ 90-fold; see materials and meth-
ods). Two BLM mutations (0.1%) were found to be present in this dataset, which was significantly lower 
compared to our CRC cohort (P = 0.003534; Table 2).
Second-hit mutation analyses in tumours of BLM mutation carriers. BLM is thought to be a 
classical tumour suppressor gene11,12, suggesting that somatic events targeting the wild-type BLM allele 
may contribute to the development of CRC. Therefore, we analysed four available tumours and matched 
normal colonic tissue for loss of heterozygosity (LOH) and mutations in the BLM locus (Table  1). In 
Case Nucleotide change Mutation rs-number Sex
Age of 
onset
Familial history 
for cancera
Tumour 
available 2nd hit
Discovery cohort (n = 55)
 P008 c.3558 + 1G > T Splicing rs148969222 F 29 2CRC (2x) No N/A
 P034 c.2695C > T p.Arg899* – M 37 1CRC (2x), 2CRC (1x) Yes Tumour LOH
Replication cohort (n = 185)
 RC001 c.98 + 1G > A Splicing – F 45
Multiple 1st and 
2nd degree family 
members with 
cancer
Yes Nob
 RC002 C.1642C > T p.Gln548* rs200389141 M 38 2CRC (2x) Yes No
 RC003 c.2695C > T p.Arg899* – F 43 2CRC (6x) Yes Nob
Table 1.  Deleterious BLM mutations in patients with early-onset colorectal cancer were identified using 
whole-exome (discovery cohort) or targeted (replication cohort) resequencing. aThe number preceding 
the type of cancer indicates the familial relation, e.g. 1, first-degree relative; 2, second-degree relative. F, 
female; M, male; CRC, colorectal cancer; LOH, loss of heterozygosity; N/A, not available. bSamples were 
only analysed for tumour LOH.
Control cohort 
(1/532)
In-house control 
exomesa (2/2,329) ExACb (71/61,486)
Replication cohort (3/185)
OR: 8.67 OR: 18.99 OR: 14.15
95% CI, 
0.69–455.36 95% CI, 2.17–227.56 95% CI, 2.85–43.37
P = 0.05516 P = 0.003534 P = 0.001482
Table 2.  Enrichment analyses for known deleterious BLM mutations in early-onset CRC cases 
compared to a cohort of population-matched controls in in-house and public databases. aIn-house data 
set of sequenced exomes; bExAC, Exome Aggregation consortium10; Abbreviations: OR, odds ratio; CI, 
confidence interval.
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DNA from one tumour (P034) a clear reduction of the wild-type allele compared to the normal tissue was 
observed, suggesting loss of the wild-type BLM allele in the tumour (Fig. 2a). Subsequent genome-wide 
profiling of this tumour showed that multiple regions exhibited copy-number neutral LOH, including the 
entire q-arm of chromosome 15 on which the BLM gene is located (Fig. 2b and Supplementary Figure 2). 
On the remaining three tumours second-hit mutation analysis was performed using MIP-based sequenc-
ing of the entire coding region of BLM. However, due to poor quality and low quantity of the DNA this 
analysis was only successful for one tumour (RC002), which did not reveal additional somatic mutations 
in the coding region of BLM.
Risk for CRC in heterozygous BLM mutation carriers. Next, we collected clinical information 
from all five CRC patients in which we identified the BLM mutations, as well as from members of the 
corresponding families (Fig.  1b). Several first-degree relatives of index cases P034 and RC001 have a 
history of CRC, and cases P008, RC002 and RC003 have multiple second-degree relatives with CRC. The 
affected sister of case RC001 was found to be carrier of a pathogenic MSH2 mutation (data not shown), 
which was not present in the BLM mutation-positive proband. We were unsuccessful in collecting DNA 
from the parents of the probands or other family members to perform co-segregation analyses. However, 
all identified BLM mutations have previously been described9 and reported in the data from the ExAC 
browser, strongly suggesting that they are inherited from either one of the parents.
Discussion
Using exome sequencing we previously identified two individuals with early-onset CRC (≤ 45 years of 
age) that carried a deleterious BLM mutation in a cohort of 55 CRC cases (de Voer et al. unpublished 
data). We estimated that on average only one in every 900 individuals in the general population is a car-
rier of a known deleterious BLM mutation, indicating an enrichment of BLM mutation carriers amongst 
individuals that develop CRC at an early age. Targeted re-sequencing of the BLM locus in an additional 
cohort of cases and controls confirmed this enrichment in individuals with early-onset CRC. In the 
tumour of one of these individuals, the BLM gene was found to be completely inactivated by somatic loss 
of the wild-type allele. Analyses of the familial histories for cancer revealed that carriers of a heterozy-
gous deleterious BLM mutation most likely have a low-to-moderate penetrant risk for developing CRC.
As yet, precise estimations of the carrier rate of pathogenic BLM mutations in the general population 
have not been reported. Based on data from the Exome Aggregation Consortium10, the prevalence of 
pathogenic BLM mutations is 0.11%. However, in certain populations, such as in people from Ashkenazi 
Jewish ancestry, carrier frequencies may be as high as 1%4. Previous research on the risk for developing 
CRC in carriers with a pathologic BLM mutation has mainly focused on this latter group. Studies in mice 
have shown that the genetic background and levels of BLM protein may have an effect on the degree of 
tumour susceptibility13–15, which suggests that other genetic and/or environmental factors may influence 
the penetrance of mutant BLM alleles. This observation may explain why previous studies, which only 
focused on the Askenazi founder mutation4–6, have not been able to provide conclusive evidence of such 
an association.
Approximately 45% of registered Bloom syndrome patients have developed one or multiple malig-
nancies. In approximately 12% of Bloom syndrome patients CRC was diagnosed7. Unfortunately, there 
Figure 2. Loss of heterozygosity analyses of the deleterious BLM mutation in the tumour of P034.  
(a) Sanger sequencing results of the region around the variants in reference DNA, DNA from normal- and 
tumour tissue from the patient, showing a loss of the wild-type C-allele in the tumour. (b) B-allele frequency 
plot of chromosome 15 showing the loss of heterozygosity along the entire chromosome 15 in the tumour 
of individual P034 (top) as compared to a reference (bottom). A blue arrow on the top ideogram marks the 
BLM locus.
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are no reports on the incidence of CRC in family members of patients with BLM syndrome that have 
developed CRC. However, based on the incidence of CRC in Bloom syndrome patients, the penetrance 
for carriers will likely be even lower, and a pronounced family history for CRC in these individuals is 
not expected. Next to CRC, heterozygous truncating mutations in BLM have also been associated with 
an increased risk for breast cancer3. In two of the five families in which we identified BLM mutations 
one or more female relatives were indeed diagnosed with breast cancer. Unfortunately, we were unable 
to perform segregation analyses, so it therefore remains to be established whether these family members 
were also carriers of BLM mutations. However, as not all carriers of deleterious BLM mutations develop 
CRC or breast cancer, additional moderate penetrant risk factors or modifiers most likely influence 
cancer risk in these carriers. This latter hypothesis is in line with the idea that the risk for CRC at an 
early age is the result of an interplay between multiple moderate-to-low penetrant genetic and/or envi-
ronmental risk factors.
Whether complete loss of BLM is necessary for the development of CRC in these heterozygous car-
riers is currently unclear. Studies in mice have suggested that monoallelic BLM mutations can induce 
tumorigenesis due to haploinsufficiency14, which suggests that additional loss of the wild-type allele is 
not strictly required for tumour initiation. In line with this, a recent study revealed that breast cancers 
from BLM mutation carriers did not show somatic inactivation of the wild-type BLM allele16. Analyses 
of a larger group of tumours from BLM mutation carriers is needed to establish the exact molecular 
mechanism by which heterozygous BLM mutations initiate tumorigenesis.
So far, deleterious BLM mutations have not been described in other whole-exome sequencing studies 
focusing on the identification of novel genetic risk factors for CRC. A possible explanation for this dis-
cordance is that these studies focused on families in which the index patient had at least one first degree 
relative affected by CRC or families in which the onset of the disease occurred at a later age, rather than 
on the group of early-onset non-familial cases that we present in this study17–19. Our study is slightly 
underpowered due to the limiting number of early-onset CRC cases that were available for mutation 
analyses. However, all comparisons between our discovery and replication cohorts, and the publically 
and in-house available control cohorts reveal an enrichment of deleterious BLM mutation in early-onset 
CRC cases. Validation of our findings in another non-Ashkenazi population will substantiate the role of 
heterozygous BLM mutations and the risk for CRC.
In conclusion, carriers of deleterious BLM mutations may have an increased risk for developing CRC 
at an early age, and this risk is most likely influenced by other moderate-to-low penetrant risk factors. 
Further knowledge on whether BLM acts as a classical tumour suppressor gene and/or whether other 
risk factors are necessary to initiate tumorigenesis, will allow for a more precise estimation of the CRC 
risk of heterozygous BLM mutation carriers.
Materials and Methods
Study cohorts. The discovery cohort consisted of 55 CRC cases, diagnosed at ≤ 45 years of age, with-
out polyposis or a mismatch repair deficiency20,21, which were referred to the Radboud university medical 
center, Nijmegen, the Netherlands. The replication cohort was composed of 185 CRC cases without mis-
match-repair deficiency from Nijmegen, The Netherlands and Dresden, Germany, diagnosed before the 
age of 50, either in the absence or presence of a family history of CRC. All participants provided written 
informed consent. The study was approved by the Committee on Research involving Human Subjects of 
the region Arnhem-Nijmegen (Commissie Mensgebonden Onderzoek (CMO) Regio Arnhem-Nijmegen; 
study number 2009/256), the Netherlands. The study was conducted in accordance with the approved 
guidelines.
Control cohorts and enrichment analysis. The control cohort for targeted resequencing con-
sisted of 532 irreversibly anonymized DNA samples extracted from peripheral blood from individuals 
with European ancestry. In addition, we retrieved all known pathogenic BLM mutations reported in 
the Bloom’s syndrome registry (http://weill.cornell.edu/bsr/)9 from the Exome Aggregation Consortium 
(ExAC)10, and from a cohort of 2,329 individuals of which in-house paired-end sequencing data were 
available with a > 90-fold median coverage (Agilent V4 kit, Agilent Technologies, Santa Clara, CA, USA; 
Illumina HiSeq 2500; Illumina, San Diego, CA, USA). These latter exomes were sequenced as a part of 
routine diagnostic testing for multiple conditions, excluding hereditary cancers, at the department of 
Human Genetics, Nijmegen, the Netherlands21, and the data were analysed anonymously. We calculated 
that our replication study, with the above-mentioned CRC and control sample sizes, would result in a 
power of 70%. Power calculations and the Fisher’s exact test to calculate odds ratio’s (OR) and signifi-
cance of differences between the CRC cohort and control cohorts were performed using the statistical 
software package R (http://www.R-project.org/).
Targeted resequencing by molecular inversion probes. Molecular inversion probes (MIPs) 
were designed as described by the procedure of O’Roak et al.8 against the coding region and at least 
20 nucleotide intronic sequences up- and downstream of each exon of the BLM gene. Aliquots of 
each 70-mer oligonucleotide probe (Integrated DNA Technologies, Coralville, IA, USA) were pooled 
at equimolar ratios and the 5′ -end of each probe was phosphorylated using T4 polynucleotide Kinase 
(New England Biolabs, Ipswich, MA, USA). Genomic DNA was prepared from peripheral blood 
www.nature.com/scientificreports/
6Scientific RepoRts | 5:14060 | DOi: 10.1038/srep14060
cells or paraffin embedded formalin-fixed (tumour or normal colonic) tissue using standard pro-
cedures. MIP-based target enrichment was performed as described previously with minor mod-
ifications8,22. Briefly, 100 ng of genomic DNA was used to capture the target regions. DNA, the 
phosphorylated MIP pool, dNTPs, polymerase and ligase were pooled, denatured for 10 min at 95 °C and 
MIP capture was performed for 22 h at 60 °C. After an exonuclease treatment a PCR was performed 
to amplify the captured material together with forward and barcoded reverse primers suitable for 
Ion Torrent PGM sequencing: 5′ -CCTCTCTATGGGCAGTCGGTGATATCGGGAAGCTGAAG-3′ 
and 5′ - CCATCTCATCCCTGCGTGTCTCCGACTCAGXXXXXXXXACGATATCCGACGGTAGTGT-
3′ (XXXXXXXX represents the 8 bp barcode). The resulting PCR products were pooled and purified 
twice using Ampure XP beads (Agencourt, Beckman Coulter, Pasadena, CA, USA) according to the man-
ufacturer’s protocol. This final library was diluted for use in a 200 bp amplification run on an OneTouch 
emulsion PCR system (Life Technologies, Carlsbad, CA, USA). The resulting Ion spheres were run on 
an Ion Torrent PGM sequencing platform (Life Technologies). Reads were aligned to UCSC human 
genome assembly hg19 and called and annotated using SequencePilot (JSI medical systems, Ettenheim, 
Germany). All variants called with a minimal variant percentage of 20% and a minor allele frequency 
of < 1% in dbSNP138 were selected for further analyses. Frameshift variants adjacent to homopoly-
meric nucleotide repeats that occurred in ≥ 10% of the samples were excluded as these were considered 
platform-specific artefacts. Variants predicted to be deleterious were validated using Sanger sequencing.
LOH and copy-number analyses. Locus-specific loss of heterozygosity (LOH) analyses were per-
formed using DNA extracted from tumour material and adjacent normal tissue. The respective DNA 
fractions were used to perform PCRs generating small amplicons covering the patient-specific muta-
tions, which were sequenced by Sanger sequencing (primers and conditions available upon request). 
Genome-wide SNP array analysis of tumour DNA was performed using the OncoScan FFPE Express 
service (Affymetrix, Santa Clara, CA, USA). The SNP array data were analysed using the Nexus Copy 
Number software package (Biodiscovery, Hawthorne, CA, USA).
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